323 related articles for article (PubMed ID: 28534357)
1. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.
Erdem GU; Altundag K; Ozdemir NY; Sahin S; Demirci NS; Karatas F; Bozkaya Y; Aytekin A; Tasdemir V; Aslan AC; Sever AR; Zengin N
J BUON; 2017; 22(2):365-376. PubMed ID: 28534357
[TBL] [Abstract][Full Text] [Related]
2. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
[TBL] [Abstract][Full Text] [Related]
3. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
4. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
[No Abstract] [Full Text] [Related]
5. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis.
Dieci MV; Barbieri E; Piacentini F; Ficarra G; Bettelli S; Dominici M; Conte PF; Guarneri V
Ann Oncol; 2013 Jan; 24(1):101-8. PubMed ID: 23002281
[TBL] [Abstract][Full Text] [Related]
6. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer.
Shiino S; Kinoshita T; Yoshida M; Jimbo K; Asaga S; Takayama S; Tsuda H
Clin Breast Cancer; 2016 Aug; 16(4):e133-40. PubMed ID: 27268749
[TBL] [Abstract][Full Text] [Related]
8. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of receptor discordance between primary and recurrent breast cancer.
Matsumoto A; Jinno H; Murata T; Seki T; Takahashi M; Hayashida T; Kameyama K; Kitagawa Y
Int J Clin Oncol; 2015 Aug; 20(4):701-8. PubMed ID: 25348193
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer.
Sari E; Guler G; Hayran M; Gullu I; Altundag K; Ozisik Y
Med Oncol; 2011 Mar; 28(1):57-63. PubMed ID: 20099049
[TBL] [Abstract][Full Text] [Related]
12. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
[TBL] [Abstract][Full Text] [Related]
13. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
Aurilio G; Disalvatore D; Pruneri G; Bagnardi V; Viale G; Curigliano G; Adamoli L; Munzone E; Sciandivasci A; De Vita F; Goldhirsch A; Nolè F
Eur J Cancer; 2014 Jan; 50(2):277-89. PubMed ID: 24269135
[TBL] [Abstract][Full Text] [Related]
15. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
16. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
Ma XM; Han YW; Zhang J; Cui WJ; Wang X
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):372-6. PubMed ID: 24054015
[TBL] [Abstract][Full Text] [Related]
17. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
18. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
Amir E; Clemons M; Purdie CA; Miller N; Quinlan P; Geddie W; Coleman RE; Freedman OC; Jordan LB; Thompson AM
Cancer Treat Rev; 2012 Oct; 38(6):708-14. PubMed ID: 22178456
[TBL] [Abstract][Full Text] [Related]
19. Discordance in receptor status between primary and metastatic breast cancer and overall survival: A single-center analysis.
Mellouli M; Graja S; Kridis WB; Ayed HB; Makni S; Triki M; Charfi S; Khanfir A; Boudawara TS; Kallel R
Ann Diagn Pathol; 2022 Dec; 61():152044. PubMed ID: 36099874
[TBL] [Abstract][Full Text] [Related]
20. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
